These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A multimodal disease modifying approach to treat neuropathic pain--inhibition of soluble epoxide hydrolase (sEH). Pillarisetti S; Khanna I Drug Discov Today; 2015 Nov; 20(11):1382-90. PubMed ID: 26259523 [TBL] [Abstract][Full Text] [Related]
5. Distribution of soluble and microsomal epoxide hydrolase in the mouse brain and its contribution to cerebral epoxyeicosatrienoic acid metabolism. Marowsky A; Burgener J; Falck JR; Fritschy JM; Arand M Neuroscience; 2009 Oct; 163(2):646-61. PubMed ID: 19540314 [TBL] [Abstract][Full Text] [Related]
11. Role of epoxyeicosatrienoic acids in cardiovascular diseases and cardiotoxicity of drugs. Zhang Y; Gao L; Yao B; Huang S; Zhang Y; Liu J; Liu Z; Wang X Life Sci; 2022 Dec; 310():121122. PubMed ID: 36309225 [TBL] [Abstract][Full Text] [Related]
12. Increased epoxyeicosatrienoic acids and reduced soluble epoxide hydrolase expression in the preeclamptic placenta. Dalle Vedove F; Fava C; Jiang H; Zanconato G; Quilley J; Brunelli M; Guglielmi V; Vattemi G; Minuz P J Hypertens; 2016 Jul; 34(7):1364-70. PubMed ID: 27115337 [TBL] [Abstract][Full Text] [Related]
13. Epoxyeicosatrienoic acid pathway in human health and diseases. Bellien J; Joannides R J Cardiovasc Pharmacol; 2013 Mar; 61(3):188-96. PubMed ID: 23011468 [TBL] [Abstract][Full Text] [Related]
14. Soluble Epoxide Hydrolase Inhibitor and 14,15-Epoxyeicosatrienoic Acid-Facilitated Long-Term Potentiation through cAMP and CaMKII in the Hippocampus. Wu HF; Chen YJ; Wu SZ; Lee CW; Chen IT; Lee YC; Huang CC; Hsing CH; Tang CW; Lin HC Neural Plast; 2017; 2017():3467805. PubMed ID: 29138698 [TBL] [Abstract][Full Text] [Related]
15. Epoxyeicosatrienoic acids and soluble epoxide hydrolase in physiology and diseases of the central nervous system. Kuo YM; Lee YH Chin J Physiol; 2022; 65(1):1-11. PubMed ID: 35229747 [TBL] [Abstract][Full Text] [Related]
16. Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease. Elmarakby AA Am J Physiol Regul Integr Comp Physiol; 2012 Feb; 302(3):R321-30. PubMed ID: 22116511 [TBL] [Abstract][Full Text] [Related]
17. Acute arsenic toxicity alters cytochrome P450 and soluble epoxide hydrolase and their associated arachidonic acid metabolism in C57Bl/6 mouse heart. Anwar-Mohamed A; El-Sherbeni AA; Kim SH; Althurwi HN; Zordoky BN; El-Kadi AO Xenobiotica; 2012 Dec; 42(12):1235-47. PubMed ID: 22680237 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation. Fife KL; Liu Y; Schmelzer KR; Tsai HJ; Kim IH; Morisseau C; Hammock BD; Kroetz DL J Pharmacol Exp Ther; 2008 Dec; 327(3):707-15. PubMed ID: 18815352 [TBL] [Abstract][Full Text] [Related]
19. CYP450 Epoxygenase Metabolites, Epoxyeicosatrienoic Acids, as Novel Anti-Inflammatory Mediators. Shi Z; He Z; Wang DW Molecules; 2022 Jun; 27(12):. PubMed ID: 35744996 [TBL] [Abstract][Full Text] [Related]
20. The Role of Soluble Epoxide Hydrolase Enzyme on Daunorubicin-Mediated Cardiotoxicity. Maayah ZH; Abdelhamid G; Elshenawy OH; El-Sherbeni AA; Althurwi HN; McGinn E; Dawood D; Alammari AH; El-Kadi AOS Cardiovasc Toxicol; 2018 Jun; 18(3):268-283. PubMed ID: 29196978 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]